Congenital hypophosphatasia is absence or low levels of serum alkaline phosphatase due to mutations in the gene encoding tissue-nonspecific alkaline phosphatase (TNSALP).
Because serum alkaline phosphatase is absent or decreased, calcium is not diffusely deposited in bones, causing low bone density and hypercalcemia. Alkaline phosphatase deficiency also causes intracellular pyridoxine deficiency (vitamin B6 deficiency), which can cause generalized seizures. Vomiting, inability to gain weight, and enlargement of the epiphyses (similar to that in rickets) usually occur. Patients who survive infancy have bony deformities and short stature, but mental development is normal.
Asfotase alfa, a recombinant protein carrying the catalytic domain of tissue-nonspecific alkaline phosphatase, can be given by subcutaneous injection for treatment of congenital hypophosphatasia. Dosing is 2 mg/kg 3 times a week or 1 mg/kg 6 times a week; if needed, dose can be increased to 3 mg/kg 3 times a week in children with disease beginning perinatally or during infancy.
Vitamin B6 in high doses may reduce seizures: 15 to 60 mg/kg (maximum dose is 100 mg) IV is given once for an active seizure, followed by a weight-adjusted maintenance dose, typically 50 to 100 mg (up to a maximum dose of 500 mg) orally once a day.
Nonsteroidal anti-inflammatory drugs (NSAIDs) reduce bone pain.
Infusions of alkaline phosphatase and hematopoietic stem cell transplantation have limited roles.
